Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Arrow recall benefits Utah Medical: Salt Lake City firm's neonatal sales rise 28% in Q1 as former customers of Arrow International's NeoPICC 1.9 Fr peripheral central catheter, voluntarily recalled in December, purchase Utah Medical's products as replacements, CEO Kevin Cornwell states in April 21 call (1"The Gray Sheet" Jan. 24, 2005, p. 26). In the first quarter, Utah Medical revenue totaled $6.7 mil., up 1% versus the prior-year period. The firm's obstetrics product sales slipped 6%, hampering growth....FDA v. Utah Medical: Exec notes a Department of Justice complaint seeking to halt Utah Medical sales after an FDA inspection cited persistent QSR lapses dating to 2001 is slated for a June 20 pre-trial hearing in Salt Lake City federal court (2"The Gray Sheet" Aug. 23, 2004, In Brief)...

You may also be interested in...



Bausch & Lomb Predicts Strong Sales From PureVision Re-Launch In U.S.

Bausch & Lomb's planned U.S. re-launch of its PureVision silicone hydrogel contact lens in the second quarter could enable a repeat of the firm's 12% constant currency lens sales growth for 2004

Arrow Upgrades Manufacturing/Sales Operations, Reviews LVAD Program

Arrow International expects to spend $40 mil. over the next two years to streamline its global manufacturing operations, the company reported during a Jan. 19 annual shareholders meeting

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

UsernamePublicRestriction

Register

MT021998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel